Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro

31 Dec 2020

Abstract excerpt

The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus poses serious threats to the global public health and leads to worldwide crisis. No effective drug or vaccine is readily available. The viral RNA-dependent RNA polymerase (RdRp) is a promising therapeutic target. A hybrid drug screening procedure was proposed and applied to identify potential drug candidates targeting RdRp from 1906...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Plant Virus Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33382685
DOI: 10.1371/journal.pcbi.1008489

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitroPMID 33382685Read ↗

Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting virusesSemantic proximity Read ↗

Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approachSemantic proximity Read ↗

Recent advancements in the discovery of small-molecule non-nucleoside inhibitors targeting SARS-CoV-2 RdRpSemantic proximity Read ↗

A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp)Semantic proximity Read ↗

Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymeraseSemantic proximity Read ↗

An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challengesSemantic proximity Read ↗

Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2Semantic proximity Read ↗

Identification of Potent Drugs and Antiviral Agents for the Treatment of the SARS-CoV-2 InfectionSemantic proximity Read ↗

RNA‐dependent RNA polymerase of SARS‐CoV‐2 as a therapeutic targetSemantic proximity Read ↗

Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2Semantic proximity Read ↗

Potential use of RNA-dependent RNA polymerase (RdRp) inhibitors against SARS-CoV2 infectionSemantic proximity Read ↗

Insights into RNA-dependent RNA Polymerase Inhibitors as Antiinfluenza Virus AgentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.